Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Fludara in Indolent Lymphoma
NCT00688883Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2003
- Primary completion
- Aug 2004
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine in lymphoma and mantle cell lymphoma (MCL), sponsored by Sanofi. Primary endpoint: Best overall response rate. Started Feb 2003; status: completed.
02
Drugs
fludarabine
03
Conditions
lymphomamantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00688883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00688883.